KYMR – Kymera Therapeutics, Inc.
KYMR — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
13.57
Margin Of Safety %
Put/Call OI Ratio
0.7
EPS Next Q Diff
-0.41
EPS Last/This Y
0.18
EPS This/Next Y
-0.84
Price
107.49
Target Price
130.91
Analyst Recom
1.29
Performance Q
Upside
-139.2%
Beta
1.95
Ticker: KYMR
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | KYMR | 110.43 | 0.74 | 1.21 | 10143 |
| 2026-07-14 | KYMR | 111.93 | 0.75 | 0.47 | 10224 |
| 2026-07-15 | KYMR | 114.19 | 0.74 | 1.57 | 10312 |
| 2026-07-16 | KYMR | 113.86 | 0.75 | 0.77 | 10350 |
| 2026-07-17 | KYMR | 115.74 | 0.75 | 0.10 | 10413 |
| 2026-07-20 | KYMR | 111.09 | 0.67 | 2.63 | 9392 |
| 2026-07-21 | KYMR | 113.36 | 0.67 | 2.21 | 9430 |
| 2026-07-22 | KYMR | 110.33 | 0.67 | 0.13 | 9479 |
| 2026-07-23 | KYMR | 110.39 | 0.66 | 1.11 | 9650 |
| 2026-07-24 | KYMR | 110.51 | 0.67 | 0.00 | 9703 |
| 2026-07-27 | KYMR | 110.08 | 0.66 | 0.00 | 9709 |
| 2026-07-28 | KYMR | 106.08 | 0.66 | 1.18 | 9723 |
| 2026-07-29 | KYMR | 105.38 | 0.67 | 0.11 | 9824 |
| 2026-07-30 | KYMR | 106.99 | 0.67 | 35.00 | 9832 |
| 2026-07-31 | KYMR | 103.31 | 0.67 | 0.47 | 9884 |
| 2026-08-03 | KYMR | 100.17 | 0.67 | 15.80 | 9891 |
| 2026-08-04 | KYMR | 104.59 | 0.69 | 1.39 | 9968 |
| 2026-08-05 | KYMR | 105.48 | 0.69 | 0.15 | 9999 |
| 2026-08-06 | KYMR | 106.41 | 0.70 | 0.00 | 9926 |
| 2026-08-07 | KYMR | 107.62 | 0.70 | 1.40 | 9927 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | KYMR | 110.51 | 21.7 | - | -3.52 |
| 2026-07-14 | KYMR | 112.02 | 21.7 | - | -3.52 |
| 2026-07-15 | KYMR | 114.23 | 21.7 | - | -3.51 |
| 2026-07-16 | KYMR | 113.93 | 21.7 | - | -3.51 |
| 2026-07-17 | KYMR | 115.74 | 21.7 | - | -3.51 |
| 2026-07-20 | KYMR | 111.11 | 21.7 | - | -3.51 |
| 2026-07-21 | KYMR | 113.36 | 21.7 | - | -3.51 |
| 2026-07-22 | KYMR | 110.34 | 21.7 | - | -3.51 |
| 2026-07-23 | KYMR | 110.36 | 21.7 | - | -3.51 |
| 2026-07-24 | KYMR | 110.53 | 21.7 | - | -3.51 |
| 2026-07-27 | KYMR | 110.10 | 21.7 | - | -3.51 |
| 2026-07-28 | KYMR | 106.11 | 21.7 | - | -3.51 |
| 2026-07-29 | KYMR | 105.28 | 21.7 | - | -3.51 |
| 2026-07-30 | KYMR | 106.81 | 21.7 | - | -3.51 |
| 2026-07-31 | KYMR | 103.34 | 21.7 | - | -3.51 |
| 2026-08-03 | KYMR | 100.23 | 21.7 | - | -3.51 |
| 2026-08-04 | KYMR | 100.23 | 21.7 | - | -3.51 |
| 2026-08-05 | KYMR | 105.43 | 22.3 | - | -3.51 |
| 2026-08-06 | KYMR | 106.37 | 22.3 | - | -3.51 |
| 2026-08-07 | KYMR | 107.49 | -9.4 | - | -3.51 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | KYMR | -30.08 | 4.04 | 13.90 |
| 2026-07-14 | KYMR | -30.08 | 4.04 | 13.90 |
| 2026-07-15 | KYMR | -30.08 | 4.04 | 13.90 |
| 2026-07-16 | KYMR | -30.08 | 4.04 | 13.90 |
| 2026-07-17 | KYMR | -30.08 | 4.04 | 13.90 |
| 2026-07-20 | KYMR | -30.08 | 3.31 | 13.90 |
| 2026-07-21 | KYMR | -30.11 | 3.31 | 13.90 |
| 2026-07-22 | KYMR | -30.11 | 3.31 | 13.90 |
| 2026-07-23 | KYMR | -30.11 | 3.31 | 13.90 |
| 2026-07-24 | KYMR | -30.11 | 3.31 | 13.90 |
| 2026-07-27 | KYMR | -30.11 | 3.42 | 13.56 |
| 2026-07-28 | KYMR | -30.11 | 3.42 | 13.56 |
| 2026-07-29 | KYMR | -30.11 | 3.42 | 13.56 |
| 2026-07-30 | KYMR | -30.11 | 3.42 | 13.56 |
| 2026-07-31 | KYMR | -30.11 | 3.42 | 13.56 |
| 2026-08-03 | KYMR | -30.11 | 3.07 | 13.56 |
| 2026-08-04 | KYMR | -30.11 | 3.07 | 13.57 |
| 2026-08-06 | KYMR | -30.02 | 3.07 | 13.57 |
| 2026-08-07 | KYMR | -30.02 | 3.07 | 13.57 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.62
Avg. EPS Est. Current Quarter
-1.03
Avg. EPS Est. Next Quarter
-1.03
Insider Transactions
-30.02
Institutional Transactions
3.07
Beta
1.95
Average Sales Estimate Current Quarter
7
Average Sales Estimate Next Quarter
10
Fair Value
Quality Score
31
Growth Score
34
Sentiment Score
55
Actual DrawDown %
17.3
Max Drawdown 5-Year %
-83.5
Target Price
130.91
P/E
Forward P/E
PEG
P/S
85.15
P/B
5.9
P/Free Cash Flow
EPS
-3.24
Average EPS Est. Cur. Y
-3.51
EPS Next Y. (Est.)
-4.36
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-285.34
Relative Volume
0.58
Return on Equity vs Sector %
-47.2
Return on Equity vs Industry %
-31.1
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
◆
KYMR
Healthcare
$107.52
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
51.9
Range 1M
34.7%
Sup Dist
3.1%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-1.8%
52W%
75.1%
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+21.8% upside
Upside
+21.8%
Quality
31
KYMR — P/E HistoricalBiotechnology
Kymera Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 273
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
KYMR
Latest News
—
Caricamento notizie per KYMR…
stock quote shares KYMR – Kymera Therapeutics, Inc. Stock Price stock today
news today KYMR – Kymera Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch KYMR – Kymera Therapeutics, Inc. yahoo finance google finance
stock history KYMR – Kymera Therapeutics, Inc. invest stock market
stock prices KYMR premarket after hours
ticker KYMR fair value insiders trading